<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333668</url>
  </required_header>
  <id_info>
    <org_study_id>PCCWUAR</org_study_id>
    <nct_id>NCT03333668</nct_id>
  </id_info>
  <brief_title>Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents</brief_title>
  <acronym>AGUALIS</acronym>
  <official_title>Experimental fMRI Study on the Comparison of the Brain Function Effects of a Single Dose of Guanfacine and Lisdexamfetamine Relative to Placebo in Children and Adolescents With ADHD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is not a clinical trial. The aim of this study is to understand the mechanism of action
      of two recently licensed drugs for ADHD on brain function. We will compare the brain
      activation changes elicited by Guanfacine extended release (GXR; a non-stimulant drug) with
      the brain activation changes elicited by Lisdexamfetamine (LISDEX; a stimulant drug) and by
      placebo in 20 drug−naïve patients with ADHD using functional Magnetic Resonance Imaging
      (fMRI). For this purpose we intend to scan participants during their performance of tasks of
      attention, working memory, and inhibition, which we know from previous studies to elicit
      abnormal brain activation patterns in ADHD patients (Rubia et al., 2005; Smith et al., 2006).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty ADHD male patients between 10 and 18 years will participate in the double-blind,
      randomised, active drug condition, within-group, placebo-controlled experimental fMRI study.
      Each participant will be assessed in baseline measures during a pre-assessment visit. Then
      the patient will be scanned 3 times under each of these 3 drug conditions: GXR, LISDEX, and
      placebo. Every patient will receive a single typical clinical weight-adjusted dose of GXR
      (0.05mg/kg), LISDEX (30mg for smaller, 50mg for larger boys) and placebo (10mg Vit C) in one
      of the scans, in a randomised order. Patients will be scanned 4.5 hours after drug
      administration (where drugs have shown to have maximum plasma concentration). They will be
      scanned 3 times, one week apart, under each drug condition.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each participant will complete all three experimental conditions (LISDEX, GXR, placebo) in a randomised order.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in brain activation under the three drug conditions (LISDEX, GXR, placebo)</measure>
    <time_frame>2 weeks (3 hourly scans one week apart)</time_frame>
    <description>Brain activation as measured by blood-oxygen-level-dependent (BOLD) response obtained by fMRI for each of the 3 below listed tasks and functional connectivity measures for the resting state scan.
A working memory task (N-back)
A tracking stop task
A parametric sustained attention task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in dependent variables extracted from performance on the fMRI tasks used under the three drug conditions (LISDEX, GXR, placebo)</measure>
    <time_frame>2 weeks (3 hourly scans one week apart)</time_frame>
    <description>A working memory task (N-back)
A tracking stop task
A parametric sustained attention task</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Lisdexamfetamine - Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Guanfacine - Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisdexamfetamine - Guanfacine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine dimesylate</intervention_name>
    <description>Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet</description>
    <arm_group_label>Lisdexamfetamine - Placebo</arm_group_label>
    <arm_group_label>Lisdexamfetamine - Guanfacine</arm_group_label>
    <other_name>Vyvanse (Shire Pharmaceuticals Ltd.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine Extended Release Oral Tablet</intervention_name>
    <description>Guanfacine Extended Release (0.05mg/kg) tablet</description>
    <arm_group_label>Guanfacine - Placebo</arm_group_label>
    <arm_group_label>Lisdexamfetamine - Guanfacine</arm_group_label>
    <other_name>Intuniv (Shire Pharmaceuticals Ltd.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vitamin C (10mg) tablet</description>
    <arm_group_label>Lisdexamfetamine - Placebo</arm_group_label>
    <arm_group_label>Guanfacine - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range: 10-18 years

          -  Gender: male

          -  Medication-naïve or on no medication for 2 or more years

          -  Handedness: right-handed

          -  Weight: 20-80 kg

          -  Meeting DSM-5 diagnosis of ADHD

          -  Score above clinical cut-off on the ADHD module of the Kiddie Schedule for Affective
             Disorders and Schizophrenia (K-SADS) (Kaufman et al., 1997)

          -  Score below clinical cut-off for ASD on the Social Communication Questionnaire (SCQ)
             (Rutter et al., 2003)

          -  Score above clinical cut-off for ADHD on the short forms of the Conners Parent Rating
             Scales, CPRS (Conners et al., 2008)

          -  Score above cut-off on the ADHD Rating Scale, ADHD-RS (DuPaul, et al., 1998)

          -  IQ &gt; 80 as tested on the WASI-II (Wechsler et al., 1999)

          -  Mood and depression symptoms will be allowed as long as they are not the primary
             diagnosis.

        Exclusion Criteria:

          -  IQ &lt; 80 (Wechsler et al., 1999).

          -  Comorbidity with schizophrenia, bipolar disorder, learning disability, autism, OCD,
             severe depression with current suicidal behaviour (as assessed by a clinical
             interview)

          -  Neurological problems, i.e. a history of severe neurological illness, e.g. brain
             tumour, epilepsy or a history of symptomatic seizures, polyneuropathy etc.

          -  Substance abuse history

          -  Other illness (cardiovascular, renal, hepatic, metabolic) that would impact the data
             integrity or safety of the subject (i.e. contraindicated to any of the treatments) as
             determined by the investigators

          -  Contraindication to MRI. i.e., previous implantation of metallic material, pacemaker,
             implanted medication pumps, neural stimulators, claustrophobia

          -  Unable to give informed assent or consent in the case of the parent

          -  Contraindications for LISDEX and GXR use (i.e. advanced arteriosclerosis, agitated
             states, hyperexcitability, hyperthyroidism, moderate or severe hypertension,
             symptomatic cardiovascular disease)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivia S Kowalczyk, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>IoPPN, King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivia S Kowalczyk, BSc</last_name>
    <phone>02078480384</phone>
    <email>oliwia.s.kowalczyk@kcl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Psychiatry, Psychology &amp; Neuroscience; King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivia S Kowalczyk, BSc</last_name>
      <phone>02078480384</phone>
      <email>oliwia.s.kowalczyk@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Olivia S Kowalczyk, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katya Rubia, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitul A Mehta, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Rubia K, Smith AB, Brammer MJ, Toone B, Taylor E. Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. Am J Psychiatry. 2005 Jun;162(6):1067-75.</citation>
    <PMID>15930054</PMID>
  </reference>
  <reference>
    <citation>Smith AB, Taylor E, Brammer M, Toone B, Rubia K. Task-specific hypoactivation in prefrontal and temporoparietal brain regions during motor inhibition and task switching in medication-naive children and adolescents with attention deficit hyperactivity disorder. Am J Psychiatry. 2006 Jun;163(6):1044-51.</citation>
    <PMID>16741205</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lisdexamfetamine</keyword>
  <keyword>Guanfacine</keyword>
  <keyword>functional Magnetic Resonance Imaging</keyword>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

